The role of CGRP in cluster headache supports ongoing trials of the remaining CGRP pathway monoclonal antibodies and gepants for preventive and acute treatment. A Panglossian view would include targeting neuropeptides involved in parasympathetic signalling in cluster headache, such as pituitary adenylate ...
Quintana S, Cevoli S, Favoni V, d'Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021 Dec 18;22(1):154. ...
4.Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets. 2020 Feb;24(2):91-100. 5.Sevivas H, Fresco P. Treatment of resistant ch...
6.Sacco S, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022 Jun 11;23(1...
which involves either CGRP receptor antagonists or monoclonal antibodies (mAbs) to CGRP or its receptor, has recently shown clinical efficacy in migraine management. The site of action, although still being studied, is likely in nervous system structures outside the blood–brain barrier. To date, ...
the treatment of preventive and acute migraine conditions, the FDA has approved drugs targeting CGRP. These include CGRP receptor antagonists, known as the gepants group (i.e., ubrogepant, rimegepant, atogepant, and zavegepant), as well as CGRP monoclonal antibodies (mAbs) like erenumab-a...
The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention.In this multicentre, randomised, double-bl...
Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies Article 作者:Annovazzi, Pietro;Solaro, Claudio Marcello;Maniscalco, Giorgia Teresa;Vercellino, Marco;Calabresi, Paolo;Nociti, Viviana;Fantozzi, Roberta;Cocco, Eleonora;Paolicelli, Damiano;Romozzi, Marina;...
the role of CGRP in the pathophysiology of migraine and the mechanism of action of monoclonal antibodies and gepants; and to critically analyse the results of different studies and the profile of patients eligible for treatment with monoclonal antibodies, and the impact in terms of pharmacoeconomics...
7. Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23(...